Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03238027 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
A Phase 1 study of Solid Tumor and Locally Advanced Malignant Neoplasm, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT03238027 is a Phase 1 study of Solid Tumor and Locally Advanced Malignant Neoplasm that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 45 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (80% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03238027, a Phase 1 study of Solid Tumor and Locally Advanced Malignant Neoplasm, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further investigation in patients with solid tumors.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Axatilimab
Study Locations (5)
Texas
- NEXT Oncology - San Antonio
- South Texas Accelerated Research Therapeutics - San Antonio
Arizona
- Honor Health - Scottsdale
Maryland
- Johns Hopkins University - Baltimore
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2020-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03238027
The ClinicalTrials.gov registry entry for NCT03238027 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (80% lower). The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT03238027 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Arizona, Maryland.
Frequently Asked Questions
What is clinical trial NCT03238027 about?
NCT03238027 is a clinical study titled "A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors". A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further investigation in patients with solid tumors.
What is the current status of trial NCT03238027?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2017-09-01. Estimated completion is 2020-11-20.
What conditions does trial NCT03238027 study?
This clinical trial studies the following conditions: Solid Tumor, Locally Advanced Malignant Neoplasm, Metastatic Tumor, Unresectable Malignant Neoplasm.
What interventions are being tested in trial NCT03238027?
The interventions under investigation include: Durvalumab (DRUG), Axatilimab (DRUG).
Who is sponsoring clinical trial NCT03238027?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03238027 being conducted?
This trial has 5 study locations across Arizona, Maryland, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.